ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bhatt, 2008, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, J Am Coll Cardiol, 52, 1502, 10.1016/j.jacc.2008.08.002
Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746
Sabatine, 2005, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 352, 1179, 10.1056/NEJMoa050522
Chen, 2005, Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, 1607, 10.1016/S0140-6736(05)67660-X
King, 2008, 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines, J Am Coll Cardiol, 51, 172, 10.1016/j.jacc.2007.10.002
Connolly, 2009, Effect of clopidogrel added to aspirin in patients with atrial fibrillation, N Engl J Med, 360, 2066, 10.1056/NEJMoa0901301
1996, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, 348, 1329, 10.1016/S0140-6736(96)09457-3
Smith, 2006, AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update, J Am Coll Cardiol, 47, 2130, 10.1016/j.jacc.2006.04.026
Bhatt, 2006, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N Engl J Med, 354, 1706, 10.1056/NEJMoa060989
Diener, 2004, Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial, Lancet, 364, 331, 10.1016/S0140-6736(04)16721-4
Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482
Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327
Adams, 2008, Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack, Stroke, 39, 1647, 10.1161/STROKEAHA.107.189063
Taha, 2009, Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial, Lancet, 374, 119, 10.1016/S0140-6736(09)61246-0
Van, 1998, Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers, Drug Metabol Drug Interact, 14, 193, 10.1515/DMDI.1998.14.3.193
Wysota, 2008, Colonic carcinoma unmasked by dual antiplatelet therapy, Eur J Intern Med, 19, 558, 10.1016/j.ejim.2008.01.008
Spaziani, 2007, [Massive lower gastrointestinal bleeding due to diverticular disease during antiplatelet therapy. Case report], G Chir, 28, 428
De Palma, 2007, Acute gastrointestinal bleeding following aortic valve replacement in a patient with Heyde's sindrome, Minerva Gastroenterol Dietol, 53, 291
Caruana, 2007, Risk of massive upper gastrointestinal bleeding in gastric bypass patients taking clopidogrel, Surg Obes Relat Dis, 3, 443, 10.1016/j.soard.2006.12.008
Nelson, 2009, Risk of bleeding following hemorrhoidal banding in patients on antithrombotic therapy, Gastroenterol Clin Biol, 33, 463, 10.1016/j.gcb.2009.05.007
Nelson, 2008, Risk of late bleeding following hemorrhoidal banding in patients on antithrombotic prophylaxis, Am J Surg, 196, 994, 10.1016/j.amjsurg.2008.07.036
Hui, 2004, Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases, Gastrointest Endosc, 59, 44, 10.1016/S0016-5107(03)02307-1
Singh, 2010, Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy, Gastrointest Endosc, 71, 998, 10.1016/j.gie.2009.11.022
Hernandez-Diaz, 2000, Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s, Arch Intern Med, 160, 2093, 10.1001/archinte.160.14.2093
Ng, 2008, Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel, J Gastroenterol, 43, 679, 10.1007/s00535-008-2215-4
Ng, 2008, Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy, Digestion, 77, 173, 10.1159/000141264
Ng, 2008, Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome, Am J Gastroenterol, 103, 865, 10.1111/j.1572-0241.2007.01715.x
Barada, 2008, Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors, J Clin Gastroenterol, 42, 368, 10.1097/MCG.0b013e31802e63ff
Nikolsky, 2007, Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach, Eur Heart J, 28, 1936, 10.1093/eurheartj/ehm194
Nikolsky, 2004, Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention, Am J Cardiol, 94, 300, 10.1016/j.amjcard.2004.04.023
Nikolsky, 2003, Understanding the consequences of contrast-induced nephropathy, Rev Cardiovasc Med, 4, S10
Ray, 2010, Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study, Ann Intern Med, 152, 337, 10.7326/0003-4819-152-6-201003160-00003
Moukarbel, 2009, Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial, Eur Heart J, 30, 2226, 10.1093/eurheartj/ehp256
Abbas, 2005, Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction, Am J Cardiol, 96, 173, 10.1016/j.amjcard.2005.03.038
Fork, 2000, Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers, Scand J Gastroenterol, 35, 464, 10.1080/003655200750023705
Abraham, 2005, NSAIDs and gastrointestinal complications: new clinical challenges, Expert Opin Pharmacother, 6, 2681, 10.1517/14656566.6.15.2681
Ma, 2001, Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release, Proc Natl Acad Sci U S A, 98, 6470, 10.1073/pnas.111150798
Jones, 1987, Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs, Gut, 28, 1120, 10.1136/gut.28.9.1120
Howden, 1990, The relationship between suppression of acidity and gastric ulcer healing rates, Aliment Pharmacol Ther, 4, 25, 10.1111/j.1365-2036.1990.tb00445.x
Lanas, 2007, Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants, Am J Gastroenterol, 102, 507, 10.1111/j.1572-0241.2006.01062.x
Laine, 2010, Proton pump inhibitor and clopidogrel interaction: fact or fiction?, Am J Gastroenterol, 105, 34, 10.1038/ajg.2009.638
Bhatt, 2010, Clopidogrel with or without omeprazole in coronary artery disease, N Engl J Med, 10.1056/NEJMoa1007964
Gurbel, 2009, Recent developments in clopidogrel pharmacology and their relation to clinical outcomes, Expert Opin Drug Metab Toxicol, 5, 989, 10.1517/17425250903107772
Kazui, 2010, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite, Drug Metab Dispos, 38, 92, 10.1124/dmd.109.029132
Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently, Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139
Hagihara, 2008, Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine, Drug Metab Pharmacokinet, 23, 412, 10.2133/dmpk.23.412
Farid, 2010, Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans, J Clin Pharmacol, 50, 126, 10.1177/0091270009343005
Ma, 2010, Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel, Pharmacol Ther, 125, 249, 10.1016/j.pharmthera.2009.10.008
Mega, 2009, Cytochrome p-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, 354, 10.1056/NEJMoa0809171
Mega, 2009, Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes, Circulation, 119, 2553, 10.1161/CIRCULATIONAHA.109.851949
Husted, 2009, Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist, Cardiovasc Ther, 27, 259, 10.1111/j.1755-5922.2009.00096.x
Capodanno, 2010, Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist, Expert Rev Cardiovasc Ther, 8, 151, 10.1586/erc.09.172
Chen, 2003, Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects, Clin Pharmacol Ther, 73, 264, 10.1067/mcp.2003.14
Feldman, 1990, Histamine2-receptor antagonists, N Engl J Med, 323, 1672, 10.1056/NEJM199012133232405
Rendic, 1999, Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic, Croat Med J, 40, 357
Welage, 2005, Overview of pharmacologic agents for acid suppression in critically ill patients, Am J Health Syst Pharm, 62, S4, 10.1093/ajhp/62.10_Supplement_2.S4
Martinez, 1999, Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists, Clin Pharmacol Ther, 65, 369, 10.1016/S0009-9236(99)70129-3
Wolfe, 2000, Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome, Gastroenterology, 118, S9, 10.1016/S0016-5085(00)70004-7
Small, 2008, Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel, Curr Med Res Opin, 24, 2251, 10.1185/03007990802205985
Shi, 2008, Proton pump inhibitors: an update of their clinical use and pharmacokinetics, Eur J Clin Pharmacol, 64, 935, 10.1007/s00228-008-0538-y
Ishizaki, 1999, Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole, Aliment Pharmacol Ther, 13, 27, 10.1046/j.1365-2036.1999.00022.x
Roden, 2009, Clopidogrel and the concept of high-risk pharmacokinetics, Circulation, 119, 2127, 10.1161/CIRCULATIONAHA.109.865907
Nguyen, 2006, Variability of response to clopidogrel: possible mechanisms and clinical implications, Cardiol Rev, 14, 136, 10.1097/01.crd.0000188033.11188.8e
Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227
Gladding, 2008, The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial, J Am Coll Cardiol Intv, 1, 620, 10.1016/j.jcin.2008.09.008
Mehta, 2010, Dose comparisons of clopidogrel and aspirin in acute coronary syndromes, N Engl J Med, 363, 930, 10.1056/NEJMoa0909475
Luo, 2006, Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study, Clin Pharmacol Ther, 80, 33, 10.1016/j.clpt.2006.03.003
Shuldiner, 2009, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, JAMA, 302, 849, 10.1001/jama.2009.1232
Bhatt, 2009, Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?, JAMA, 302, 896, 10.1001/jama.2009.1249
Xiao, 1997, Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele, J Pharmacol Exp Ther, 281, 604
Takakubo, 1996, Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese, Pharmacogenetics, 6, 265, 10.1097/00008571-199606000-00011
Bhatt, 2008, What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?, J Am Coll Cardiol, 52, 1060, 10.1016/j.jacc.2008.06.027
Hochholzer, 2010, Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement, J Am Coll Cardiol, 55, 2427, 10.1016/j.jacc.2010.02.031
Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064
Cuisset, 2009, Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study, J Am Coll Cardiol, 54, 1149, 10.1016/j.jacc.2009.05.050
O'Donoghue, 2009, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials, Lancet, 374, 989, 10.1016/S0140-6736(09)61525-7
Siller-Matula, 2009, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel, Am Heart J, 157, 148, 10.1016/j.ahj.2008.09.017
Dunn, 2008, Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without use of clopidogrel in the CREDO trial, Circulation, 118, S815, 10.1161/circ.118.suppl_18.S_815-a
Sibbing, 2009, Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel, Thromb Haemost, 101, 714, 10.1160/TH08-12-0808
Small, 2008, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel, J Clin Pharmacol, 48, 475, 10.1177/0091270008315310
Stockl, 2010, Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor, Arch Intern Med, 170, 704, 10.1001/archinternmed.2010.34
Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA, 301, 937, 10.1001/jama.2009.261
Rassen, 2009, Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome, Circulation, 120, 2322, 10.1161/CIRCULATIONAHA.109.873497
Hill, 1965, The environment and disease: association or causation?, Proc R Soc Med, 58, 295
Sung, 2010, Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial, Ann Intern Med, 152, 1, 10.7326/0003-4819-152-1-201001050-00179
Rostom, 2002, Prevention of NSAID-induced gastroduodenal ulcers, Cochrane Database Syst Rev, 10.1002/14651858.CD002296
Lanas, 2007, Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants, Am J Gastroenterol, 102, 507, 10.1111/j.1572-0241.2006.01062.x
Ng, 2010, Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions, Gastroenterology, 138, 82, 10.1053/j.gastro.2009.09.063
Yeomans, 1998, A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs, N Engl J Med, 338, 719, 10.1056/NEJM199803123381104
Chan, 2005, Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding, N Engl J Med, 352, 238, 10.1056/NEJMoa042087